{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:19:12Z","timestamp":1783487952612,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urolithiasis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00240-018-1038-x","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T04:21:14Z","timestamp":1516335674000},"page":"453-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Current opinions on nephrolithiasis associated with primary hyperparathyroidism"],"prefix":"10.1007","volume":"46","author":[{"given":"Xiaoming","family":"Cong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"key":"1038_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2015.04.004","volume":"22","author":"J Shoag","year":"2015","unstructured":"Shoag J, Tasian GE, Goldfarb DS et al (2015) The new epidemiology of nephrolithiasis. Adv Chronic Kidney Dis 22:273\u2013278","journal-title":"Adv Chronic Kidney Dis"},{"key":"1038_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eururo.2012.03.052","volume":"62","author":"CD Scales Jr","year":"2012","unstructured":"Scales CD Jr, Smith AC, Hanley JM et al (2012) Prevalence of kidney stones in the United States. Eur Urol 62:160\u2013165","journal-title":"Eur Urol"},{"key":"1038_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1359\/JBMR.050910","volume":"21","author":"RA Wermers","year":"2006","unstructured":"Wermers RA, Khosla S, Atkinson EJ et al (2006) Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993\u20132001: an update on the changing epidemiology of the disease. J Bone Miner Res 21:171\u2013177","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"1038_CR4","first-page":"N18-23","volume":"17","author":"S Adami","year":"2002","unstructured":"Adami S, Marcocci C, Gatti D (2002) Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 17(Suppl 2):N18-23","journal-title":"J Bone Miner Res"},{"key":"1038_CR5","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1038\/nrdp.2016.33","volume":"2","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Cusano NE, Khan AA et al (2016) Primary hyperparathyroidism. Nat Rev Dis Primers 2:16033. \n                    https:\/\/doi.org\/10.1038\/nrdp.2016.33","journal-title":"Nat Rev Dis Primers"},{"key":"1038_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0094-0143(05)70257-3","volume":"27","author":"JS Rodman","year":"2000","unstructured":"Rodman JS, Mahler RJ (2000) Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin N Am 27:275\u2013285","journal-title":"Urol Clin N Am"},{"key":"1038_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/jc.2011-0569","volume":"96","author":"L Rejnmark","year":"2011","unstructured":"Rejnmark L, Vestergaard P, Mosekilde L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 96:2377\u20132385","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0002-9343(03)00201-8","volume":"115","author":"CY Pak","year":"2003","unstructured":"Pak CY, Poindexter JR, Adams-Huet B et al (2003) Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 115:26\u201332","journal-title":"Am J Med"},{"key":"1038_CR9","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1056\/NEJM196605262742105","volume":"274","author":"O Cope","year":"1966","unstructured":"Cope O (1966) The study of hyperparathyroidism at the Massachusetts general hospital. N Engl J Med 274:1174\u20131182","journal-title":"N Engl J Med"},{"key":"1038_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","volume":"374","author":"WD Fraser","year":"2009","unstructured":"Fraser WD (2009) Hyperparathyroidism. Lancet 374:145\u2013158","journal-title":"Lancet"},{"key":"1038_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jocd.2012.11.005","volume":"16","author":"SJ Silverberg","year":"2013","unstructured":"Silverberg SJ, Walker MD, Bilezikian JP (2013) Asymptomatic primary hyperparathyroidism. J Clin Densitom 16:14\u201321","journal-title":"J Clin Densitom"},{"key":"1038_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-8587(13)70083-4","volume":"1","author":"DP Macfarlane","year":"2013","unstructured":"Macfarlane DP, Yu N, Leese GP (2013) Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol 1:329\u2013340","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1038_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1023\/A:1007346727944","volume":"13","author":"K el-Reshaid","year":"1997","unstructured":"el-Reshaid K, Mughal H, Kapoor M (1997) Epidemiological profile, mineral metabolic pattern and crystallographic analysis of urolithiasis in Kuwait. Eur J Epidemiol 13:229\u2013234","journal-title":"Eur J Epidemiol"},{"key":"1038_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1590\/S1677-55382005000100006","volume":"31","author":"CR Amaro","year":"2005","unstructured":"Amaro CR, Goldberg J, Amaro JL et al (2005) Metabolic assessment in patients with urinary lithiasis. Int Braz J Urol 31:29\u201333","journal-title":"Int Braz J Urol"},{"key":"1038_CR15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1464-410X.2008.08064.x","volume":"103","author":"JH Parks","year":"2009","unstructured":"Parks JH, Coe FL, Evan AP et al (2009) Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism. BJU Int 103:670\u2013678","journal-title":"BJU Int"},{"key":"1038_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1464-410X.1988.tb04254.x","volume":"62","author":"M Fuss","year":"1988","unstructured":"Fuss M, Pepersack T, Corvilain J et al (1988) Infrequency of primary hyperparathyroidism in renal stone formers. Br J Urol 62:4\u20136","journal-title":"Br J Urol"},{"key":"1038_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1210\/jc.2008-1758","volume":"94","author":"R Eastell","year":"2009","unstructured":"Eastell R, Arnold A, Brandi ML et al (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340\u2013350","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1210\/jc.2008-1760","volume":"94","author":"SJ Silverberg","year":"2009","unstructured":"Silverberg SJ, Lewiecki EM, Mosekilde L et al (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:351\u2013365","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR19","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1210\/jc.2014-1414","volume":"99","author":"R Eastell","year":"2014","unstructured":"Eastell R, Brandi ML, Costa AG et al (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99:3570\u20133579","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR20","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2014-1413","volume":"99","author":"JP Bilezikian","year":"2014","unstructured":"Bilezikian JP, Brandi ML, Eastell R et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 99:3561\u20133569","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0039-6060(97)90357-3","volume":"121","author":"E Lundgren","year":"1997","unstructured":"Lundgren E, Rastad J, Thrufjell E et al (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121:287\u2013294","journal-title":"Surgery"},{"key":"1038_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s12020-012-9694-z","volume":"42","author":"A Garcia-Martin","year":"2012","unstructured":"Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M (2012) Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42:764\u2013766","journal-title":"Endocrine"},{"key":"1038_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1590\/S0004-27302011000500003","volume":"55","author":"TF Marques","year":"2011","unstructured":"Marques TF, Vasconcelos R, Diniz E et al (2011) Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol 55:314\u2013317","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1038_CR24","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1210\/jc.2013-1300","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Maalouf NM, Wang PY et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98:2734\u20132741","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11926-015-0523-2","volume":"17","author":"F Bandeira","year":"2015","unstructured":"Bandeira F, Cassibba S (2015) Hyperparathyroidism and bone health. Curr Rheumatol Rep 17:48. \n                    https:\/\/doi.org\/10.1007\/s11926-015-0523-2","journal-title":"Curr Rheumatol Rep"},{"key":"1038_CR26","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1210\/jc.2002-021404","volume":"88","author":"G Maruani","year":"2003","unstructured":"Maruani G, Hertig A, Paillard M et al (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88:4641\u20134648","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR27","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1210\/jc.2006-2802","volume":"92","author":"H Lowe","year":"2007","unstructured":"Lowe H, McMahon DJ, Rubin MR et al (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92:3001\u20133005","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR28","doi-asserted-by":"publisher","first-page":"128352","DOI":"10.1155\/2012\/128352","volume":"2012","author":"LM Amaral","year":"2012","unstructured":"Amaral LM, Queiroz DC, Marques TF et al (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352. \n                    https:\/\/doi.org\/10.1155\/2012\/128352","journal-title":"J Osteoporos"},{"key":"1038_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.amjmed.2004.06.037","volume":"117","author":"KM Tordjman","year":"2004","unstructured":"Tordjman KM, Greenman Y, Osher E et al (2004) Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117:861\u2013863","journal-title":"Am J Med"},{"key":"1038_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","volume":"28","author":"AA Khan","year":"2017","unstructured":"Khan AA, Hanley DA, Rizzoli R et al (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28:1\u201319","journal-title":"Osteoporos Int"},{"key":"1038_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","volume":"151","author":"SM Wilhelm","year":"2016","unstructured":"Wilhelm SM, Wang TS, Ruan DT et al (2016) The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151:959\u2013968","journal-title":"JAMA Surg"},{"key":"1038_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MED.0000000000000198","volume":"22","author":"M Pawlowska","year":"2015","unstructured":"Pawlowska M, Cusano NE (2015) An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes 22:413\u2013421","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1038_CR33","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1210\/jc.2014-4432","volume":"100","author":"G Chen","year":"2015","unstructured":"Chen G, Xue Y, Zhang Q et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100:2420\u20132424","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1590\/S0004-27302013000600002","volume":"57","author":"F Bandeira","year":"2013","unstructured":"Bandeira F, Griz L, Chaves N et al (2013) Diagnosis and management of primary hyperparathyroidism\u2013a scientific statement from the department of bone metabolism, the Brazilian society for endocrinology and metabolism. Arq Bras Endocrinol Metabol 57:406\u2013424","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1038_CR35","volume-title":"Campbell-Walsh Urology","author":"MS Pearle","year":"2007","unstructured":"Pearle MS, Lotan Y (2007) Epidemiology of renal calculi physicochemistry mineral metabolism pathogenesis of upper urinary tract calculi. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh Urology, 9th\u00a0edn. Saunders Elsevier, Philadelphia (Epub)","edition":"9"},{"issue":"Suppl 1","key":"1038_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4158\/EP10308.RA","volume":"17","author":"J Varghese","year":"2011","unstructured":"Varghese J, Rich T, Jimenez C (2011) Benign familial hypocalciuric hypercalcemia. Endocr Pract 17(Suppl 1):13\u201317","journal-title":"Endocr Pract"},{"key":"1038_CR37","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2214\/AJR.07.3160","volume":"191","author":"JM Suh","year":"2008","unstructured":"Suh JM, Cronan JJ, Monchik JM (2008) Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 191:908\u2013911","journal-title":"AJR Am J Roentgenol"},{"key":"1038_CR38","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/bmj.325.7368.807","volume":"325","author":"CL Mollerup","year":"2002","unstructured":"Mollerup CL, Vestergaard P, Frokjaer VG et al (2002) Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 325:807. \n                    https:\/\/doi.org\/10.1136\/bmj.325.7368.807","journal-title":"BMJ"},{"key":"1038_CR39","doi-asserted-by":"publisher","first-page":"C221","DOI":"10.1152\/ajpcell.00139.2014","volume":"307","author":"TI Alfadda","year":"2014","unstructured":"Alfadda TI, Saleh AM, Houillier P et al (2014) Calcium-sensing receptor 20\u00a0years later. Am J Physiol Cell Physiol 307:C221\u2013C231","journal-title":"Am J Physiol Cell Physiol"},{"key":"1038_CR40","doi-asserted-by":"publisher","first-page":"F485","DOI":"10.1152\/ajprenal.00608.2009","volume":"298","author":"D Riccardi","year":"2010","unstructured":"Riccardi D, Brown EM (2010) Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 298:F485\u2013F499","journal-title":"Am J Physiol Renal Physiol"},{"key":"1038_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1210\/jc.2006-0857","volume":"92","author":"A Scillitani","year":"2007","unstructured":"Scillitani A, Guarnieri V, Battista C et al (2007) Primary hyperparathyroidism and the presence of kidney stones are associated with different haplotypes of the calcium-sensing receptor. J Clin Endocrinol Metab 92:277\u2013283","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1530\/EJE-10-0915","volume":"164","author":"G Vezzoli","year":"2011","unstructured":"Vezzoli G, Scillitani A, Corbetta S et al (2011) Polymorphisms at the regulatory regions of the CASR gene influence stone risk in primary hyperparathyroidism. Eur J Endocrinol 164:421\u2013427","journal-title":"Eur J Endocrinol"},{"key":"1038_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MNH.0b013e3283542290","volume":"21","author":"G Vezzoli","year":"2012","unstructured":"Vezzoli G, Terranegra A, Soldati L (2012) Calcium-sensing receptor gene polymorphisms in patients with calcium nephrolithiasis. Curr Opin Nephrol Hypertens 21:355\u2013361","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1038_CR44","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1210\/jc.2013-1834","volume":"98","author":"G Vezzoli","year":"2013","unstructured":"Vezzoli G, Terranegra A, Aloia A et al (2013) Decreased transcriptional activity of calcium-sensing receptor gene promoter 1 is associated with calcium nephrolithiasis. J Clin Endocrinol Metab 98:3839\u20133847","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR45","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ndt\/gfp760","volume":"25","author":"G Vezzoli","year":"2010","unstructured":"Vezzoli G, Terranegra A, Arcidiacono T et al (2010) Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region. Nephrol Dial Transpl 25:2245\u20132252","journal-title":"Nephrol Dial Transpl"},{"key":"1038_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00428-006-0222-5","volume":"449","author":"AH Yang","year":"2006","unstructured":"Yang AH, Hsu CW, Chen JY et al (2006) Normocalcemic primary hyperparathyroidism in patients with recurrent kidney stones: pathological analysis of parathyroid glands. Virchows Arch 449:62\u201368","journal-title":"Virchows Arch"},{"key":"1038_CR47","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/ndt\/gfq433","volume":"26","author":"H Bouzidi","year":"2011","unstructured":"Bouzidi H, de Brauwere D, Daudon M (2011) Does urinary stone composition and morphology help for prediction of primary hyperparathyroidism? Nephrol Dial Transpl 26:565\u2013572","journal-title":"Nephrol Dial Transpl"},{"key":"1038_CR48","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s003450050152","volume":"17","author":"A Hesse","year":"1999","unstructured":"Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17:308\u2013315","journal-title":"World J Urol"},{"key":"1038_CR49","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4158\/EP.14.9.1133","volume":"14","author":"J Muthukrishnan","year":"2008","unstructured":"Muthukrishnan J, Hari Kumar KV, Jha R et al (2008) Distal renal tubular acidosis due to primary hyperparathyroidism. Endocr Pract 14:1133\u20131136","journal-title":"Endocr Pract"},{"key":"1038_CR50","doi-asserted-by":"publisher","first-page":"bcr2014208120","DOI":"10.1136\/bcr-2014-208120","volume":"2015","author":"TE Lo","year":"2015","unstructured":"Lo TE, Tan IT (2015) Distal renal tubular acidosis in primary hyperparathyroidism. BMJ Case Rep 2015: bcr2014208120. \n                    https:\/\/doi.org\/10.1136\/bcr-2014-208120","journal-title":"BMJ Case Rep"},{"key":"1038_CR51","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ki.2008.161","volume":"74","author":"AE Evan","year":"2008","unstructured":"Evan AE, Lingeman JE, Coe FL et al (2008) Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int 74:223\u2013229","journal-title":"Kidney Int"},{"key":"1038_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.eururo.2015.07.041","volume":"69","author":"C Turk","year":"2016","unstructured":"Turk C, Petrik A, Sarica K et al (2016) EAU guidelines on interventional treatment for urolithiasis. Eur Urol 69:475\u2013482","journal-title":"Eur Urol"},{"key":"1038_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/0002-9343(74)90812-2","volume":"56","author":"GA Lumb","year":"1974","unstructured":"Lumb GA, Stanbury SW (1974) Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 56:833\u2013839","journal-title":"Am J Med"},{"key":"1038_CR54","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0002-9343(99)00294-6","volume":"107","author":"SJ Silverberg","year":"1999","unstructured":"Silverberg SJ, Shane E, Dempster DW et al (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561\u2013567","journal-title":"Am J Med"},{"key":"1038_CR55","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1210\/jc.2004-1772","volume":"90","author":"A Grey","year":"2005","unstructured":"Grey A, Lucas J, Horne A et al (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90:2122\u20132126","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR56","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1530\/EJE-14-0877","volume":"172","author":"A Khan","year":"2015","unstructured":"Khan A, Bilezikian J, Bone H et al (2015) Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol 172:527\u2013535","journal-title":"Eur J Endocrinol"},{"key":"1038_CR57","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1245\/s10434-011-2065-9","volume":"19","author":"J Norman","year":"2012","unstructured":"Norman J, Lopez J, Politz D (2012) Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use. Ann Surg Oncol 19:1466\u20131471","journal-title":"Ann Surg Oncol"},{"key":"1038_CR58","doi-asserted-by":"publisher","first-page":"E9-18","DOI":"10.1210\/jc.2010-1221","volume":"96","author":"M Peacock","year":"2011","unstructured":"Peacock M, Bilezikian JP, Bolognese MA et al (2011) Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 96:E9-18","journal-title":"J Clin Endocrinol Metab"},{"key":"1038_CR59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/PL00013175","volume":"23","author":"CL Mollerup","year":"1999","unstructured":"Mollerup CL, Lindewald H (1999) Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. World J Surg 23:173\u2013175","journal-title":"World J Surg"},{"key":"1038_CR60","doi-asserted-by":"publisher","first-page":"E347","DOI":"10.5489\/cuaj.4218","volume":"10","author":"M Dion","year":"2016","unstructured":"Dion M, Ankawi G, Chew B et al (2016) CUA guideline on the evaluation and medical management of the kidney stone patient\u20142016 update. Can Urol Assoc J 10:E347\u2013E358","journal-title":"Can Urol Assoc J"},{"key":"1038_CR61","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.eururo.2014.10.029","volume":"67","author":"A Skolarikos","year":"2015","unstructured":"Skolarikos A, Straub M, Knoll T et al (2015) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 67:750\u2013763","journal-title":"Eur Urol"}],"container-title":["Urolithiasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00240-018-1038-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00240-018-1038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00240-018-1038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T01:13:18Z","timestamp":1547860398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00240-018-1038-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s00240-018-1038-x","relation":{},"ISSN":["2194-7228","2194-7236"],"issn-type":[{"value":"2194-7228","type":"print"},{"value":"2194-7236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]},"assertion":[{"value":"27 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Xiaoming Cong declares that he has no conflict of interests relating to this work. Author Luming Shen declares that he has no conflict of interests relating to this work. Author Xiaojian Gu declares that he has no conflict of interests relating to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}